Big Rock Partners

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NRX Pharmaceuticals

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx”) on behalf of the company's long-term shareholders. NRx is a clinical-stage pharmaceutical company. The current company was formed in May 2021 via a business combination with SPAC entity Big Rock Partners Acquisition Corp. (NASDAQ: BRPA), with NRx as the surviving, publicly traded entity. Immediately following the closing of the SPAC transaction, shares of NRx traded.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Investors to Contact the Firm

PHILADELPHIA , June 15, 2023 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx") on behalf of the company's long-term shareholders. NRx is a clinical-stage pharmaceutical company.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Shareholders to Contact the Firm

RADNOR, Pa., May 25, 2021 /PRNewswire/ -- Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (Nasdaq:BRPA).

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (Nasdaq:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with NeuroRx, Inc. ("NeuroRx" or the "Company") will take place on May 24, 2021. Stockholders of record as of April 23, 2021 (the "Record Date") are eligible to vote at the Annual Meeting.

Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx

The stock price of Big Rock Partners Acquisition (NASDAQ: BRPA) increased by 88.01%. This is why it happened.

Big Rock Partners Acquisition (BRPA) Stock: 88.01% Increase Explanation

RADNOR, Pa. and TBLISI, Georgia, April 28, 2021 /PRNewswire/ -- NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its phase 3 drug, ZYESAMI (aviptadil acetate) for critically-ill citizens of Georgia with COVID-19 Respiratory Failure.

NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia

Big Rock Partners Acquisition Corp (NASDAQ: BRPA) shares are trading higher after the company's SPAC merger target, NeuroRx, on Monday confirmed dosing of the first patient in a Phase 3 trial of ZYESAMI was announced by the NIH last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19, will study ZYESAMI to treat severely ill COVID-19 patients.

Why Shares Of Big Rock Partners Acquisition Corp Are Trading Higher Today

RADNOR, Pa., April 26, 2021 /PRNewswire/ -- Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week.

Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team

RADNOR, Pa., April 19, 2021 /PRNewswire/ -- The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx's ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis.

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

NEW YORK, NY / ACCESSWIRE / April 7, 2021 / Big Rock Partners Acquisition Corp. (Nasdaq:BRPA) ("Big Rock") today clarified the procedure for stockholder redemptions in connection with Big Rock's special meeting of stockholders called for the purpose of approving an amendment to Big Rock's amended and restated certificate of incorporation to extend the date by which Big Rock has to consummate its initial business combination from April 23, 2021 to May 24, 2021 (the "extension amendment proposal"). Proxy statements are being mailed to Big Rock stockholders of record as of March 31, 2021.

Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal

After taking a hit in recent weeks, RLFTF stock investors got some good news on its respiratory failure treatment collaboration with BRPA target NeuroRx. The post RLFTF Stock: Why Relief Therapeutics and BRPA Stock Are Soaring Today appeared first on InvestorPlace.

RLFTF Stock: Why Relief Therapeutics and BRPA Stock Are Soaring Today

The stock price of Big Rock Partners Acquisition Corp (NASDAQ: BRPA) has increased by over 60% pre-market. This is why it happened.

BRPA Stock Price Increased Over 60% Pre-Market: Why It Happened

RADNOR, Pa., March 29, 2021 /PRNewswire/ -- NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF, OTCQB:RLFTF).

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

RADNOR, Pa., March 26, 2021 /PRNewswire/ -- NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 respiratory failure (www.clinicaltrials.gov 04311697).

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure

WILMINGTON, DE and DELRAY BEACH, FL / ACCESSWIRE / March 15, 2021 / NeuroRx, Inc. ("NeuroRx"), a clinical stage-small molecule pharmaceutical company and Big Rock Partners Acquisition Corp. ("Big Rock") (NASDAQ:BRPA), a special purpose acquisition company, are pleased to announce that institutional investors have committed to a private investment of $10 million in the form of one million shares of common stock of the combined company at a price of $10.00 per share (the "PIPE"), which will close concurrently with the previously announced proposed business combination between NeuroRx and BRPA. The PIPE transaction will provide the combined company with the capital resources to better enable it to accelerate product development of its drug portfolio.

Neurorx, Inc. and Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business Combination

Alexion Pharma

NEW YORK, March 12, 2021 /PRNewswire/ --                                         If you own shares in any of the companies listed above and                             would like to discuss our investigations or have any questions concerning                                       this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP1500 Broadway, 16th Floor New York, NY 10036 (212) 682-3025(888) 593-4771 stockinfo@weisslawllp.com Bank of Fincastle (OTCM: BFTL)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Bank of Fincastle (OTCM: BFTL) in connection with the proposed acquisition of the company by First National Corporation ("First National").

SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, BRPA, and KTYB Shareholders About Its Ongoing Investigations

Star Peak Energy Transition Corp

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor...

SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations

The stock price of Big Rock Partners Acquisition Corp (NASDAQ: BRPA) has increased by 20.94%. This is why it happened.

BRPA Stock Price Increased 20.94%: Why It Happened

RADNOR, Pa., Feb. 23, 2021 /PRNewswire/ -- NeuroRx, Inc. announced today that the Phase 2b/3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has demonstrated multidimensional benefit around its...

NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

NEW YORK, Feb. 7, 2021 /PRNewswire/ -- Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the proposed merger of BRPA and NeuroRx, Inc. If you are an investor, and would like...

Lifshitz Law Firm, P.C. Announces Investigation of BRPA, CGRO, GXGX, HEC, FSRV, LCY, STPK, TPGY and VSPR

Ouster, Inc

PropTech Acquisition Corp

Colonnade Acquisition Corp.

Longview Acquisition Corp.

It may be a short week with Christmas just around the corner but that doesn't mean there's a lack of SPAC merger news to discuss. The post Top SPAC Merger News This Week: Porch.com, Butterfly Network, Ouster and More Spicy SPACs appeared first on InvestorPlace.

Top SPAC Merger News This Week: Porch.com, Butterfly Network, Ouster and More Spicy SPACs

BRPA stock is shooting higher as investors process news that Big Rock Partners will take NeuroRx public. Here's what to know.

BRPA Stock: 14 Things to Know About Big Rock Partners and the NeuroRx SPAC Merger

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Big Rock Partners Acquisition Corp. ("Big Rock" or the "Company") (NASDAQ: BRPA) in connection with the Company's proposed...

News for Big Rock Partners Stock (BRPA)